What it is
Snap-8 is a short chain of amino acids (a peptide). It is made in a lab and has eight amino acids. It is sold to cosmetics companies for anti-ageing creams and serums. On ingredient labels it is called acetyl octapeptide-3. It is a slightly longer version of argireline. Argireline is a six-amino-acid skin-care peptide from the same Spanish supplier.
The idea comes from botulinum toxin (Botox). A muscle tightens when a nerve lets out a chemical messenger. To do that, a few proteins inside the nerve ending have to zip together. Snap-8 copies a small piece of one of these proteins, called SNAP-25. The theory is that Snap-8 gets in the way of the zipping. Then less messenger comes out. This effect has only been shown in the maker’s own lab tests. No one has shown that enough Snap-8 gets through human skin to reach the nerve endings.
Snap-8 is an N-acetylated, C-terminally amidated octapeptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 (C41H70N16O16S, 1075.2 g/mol, CAS 868844-74-0). It extends the argireline hexapeptide (Ac-EEMQRR-NH2, INCI acetyl hexapeptide-8) by alanine and aspartate, and its eight residues correspond to a segment of the N-terminal region of SNAP-25 (synaptosomal-associated protein of 25 kDa).
SNAP-25, syntaxin and synaptobrevin (VAMP) form the SNARE complex that drives calcium-dependent vesicle fusion and acetylcholine release at the neuromuscular junction; botulinum toxin type A acts by cleaving SNAP-25. SNAP-25-mimetic peptides are proposed to compete with the native protein for a place in the complex, destabilising it and reducing exocytosis. For argireline this was reported in vitro by Blanes-Mira et al. (2002). For Snap-8, manufacturer data summarised in a 2020 review report 43% inhibition of glutamate release at 1.5 mM in an in-vitro assay. No receptor-binding, human pharmacokinetic or skin-penetration study specific to Snap-8 was found in PubMed.
Who made it and when
A Barcelona company called Lipotec made Snap-8. Lipotec makes active ingredients for skin-care products. It is now part of Lubrizol, a US chemical group. Snap-8 came after argireline, the company’s earlier and better-known peptide.
Argireline was described in a science journal in 2002. The team was led from Miguel Hernández University in Alicante, Spain. They called it a non-toxic, much weaker copy of botulinum toxin, meant for expression lines. Snap-8 adds two amino acids to the argireline chain. We could not confirm from an original source what year Snap-8 came out. “SNAP-8” is a brand name. Ingredient lists use the name acetyl octapeptide-3.
Argireline was reported by Blanes-Mira and colleagues (Int J Cosmet Sci 2002) as the product of a rational-design programme based on SNAP-25 sequences, with authors at the Universitas Miguel Hernández, Alicante. The paper described inhibition of neurotransmitter release with a potency similar to botulinum neurotoxin A but much lower maximal efficacy, attributed to interference with SNARE-complex formation or stability, and no in-vivo oral toxicity or primary irritation at high doses.
Snap-8, the octapeptide elongation, was commercialised by Lipotec S.A. of Barcelona, now part of Lubrizol. Errante et al. (Front Chem 2020) attribute both the peptide and its efficacy figures to Lipotec’s product documentation rather than to a peer-reviewed study. An FDA laboratory later measured argireline’s skin penetration (Kraeling et al. 2015); no comparable independent study of Snap-8 was found. PubChem lists “acetyl glutamyl heptapeptide-3” and “acetyl octapeptide-1” as synonyms; the EU CosIng inventory lists the ingredient as acetyl octapeptide-3.
What the data say
There is not much evidence, and most of it comes from the company that sells it. In a lab test, Snap-8 cut the release of a nerve messenger by about 43%. This figure comes from the maker and was repeated in a 2020 review. The maker also says wrinkles dropped by 35% on average, and by up to 62%. We found no published, expert-checked report of that study.
We found two expert-checked (peer-reviewed) studies in people. Both tested skin patches covered in tiny needles (microneedle patches). The patches held Snap-8 plus other active ingredients. So neither study shows what Snap-8 does on its own. Both studies had authors from a company that makes microneedle patches. One study reported about a 26% drop in a fine-lines score after 12 weeks. The other study had 24 people and lasted 28 days. It reported better eye wrinkles than with a plain hyaluronic-acid patch. Neither study reported any skin reactions.
The big unknown is whether Snap-8 gets into the skin. FDA scientists tested argireline, a close relative, in a cream. Most of it stayed on the skin surface. None of it reached the deeper skin.
In vitro: manufacturer data summarised by Errante et al. (2020) report 43% inhibition of glutamate release at 1.5 mM, and a mean clinical wrinkle reduction of 35% (maximum 62%); no peer-reviewed details of the clinical study exist.
Human: two indexed studies include acetyl octapeptide-3, both in hyaluronic-acid microneedle patches with co-actives. Avcil et al. (J Cosmet Dermatol 2020), a 12-week single-centre study (with arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts), reported a 25.8% decrease in fine lines and wrinkles, 15.4% higher hydration and 14.2% and 12.9% increases in dermal density and thickness, with no skin reactions. Shin et al. (Ann Dermatol 2024) compared a dissolving patch (with ascorbyl glucoside and cyclic lysophosphatidic acid) against a hyaluronic-acid-only placebo patch in 24 subjects over 28 days, reporting improved periorbital wrinkles and transepidermal water loss and no adverse effects. Both had authors from a microneedle manufacturer; neither isolates Snap-8, and microneedles bypass the stratum corneum.
Penetration: Kraeling et al. (FDA, 2015) applied a 10% argireline oil-in-water emulsion to human cadaver skin; 0.22% of the dose remained in the stratum corneum, about 0.01% reached the epidermis, and none was detected in the dermis. No equivalent data exist for Snap-8.
Regulatory picture
There are three separate points.
First, approval. Snap-8 is not an approved drug. It is sold as a skin-care (cosmetic) ingredient. The FDA does not approve cosmetics or their ingredients before they go on sale. The only exception is colour additives.
Second, compounding (when a pharmacy mixes its own products). We found no FDA review of Snap-8 for use by compounding pharmacies. So this article lists that status as unknown.
Third, enforcement. We found no FDA warning letter that names Snap-8.
The key question is whether a product is a cosmetic or a drug. The FDA says a product is a cosmetic if it makes wrinkles less visible just by moisturising. A product meant to remove wrinkles, or change how the skin works, is a drug or medical device. Drugs need FDA approval. Some products claim to relax face muscles “like Botox”. That describes a change in how the body works. The FDA treats that kind of claim as a drug claim.
Under the FD&C Act, a cosmetic is an article intended to be applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance (section 201(i)); a drug includes articles intended to affect the structure or any function of the body (section 201(g)(1)). Intended use is established by labelling and promotional claims, consumer perception, and ingredients with a known therapeutic use, and FDA states that “cosmeceutical” has no meaning under the law. FDA’s anti-aging page places products intended to remove wrinkles or increase collagen production in the drug or device category. A claim that a topical peptide inhibits neuromuscular transmission or mimics botulinum toxin describes a structure/function effect of that kind.
No NDA, IND-stage programme or registered clinical trial for Snap-8 was found (ClinicalTrials.gov, September 2026), and no FDA evaluation of it for the 503A bulks list was found. In the EU, CosIng lists acetyl octapeptide-3 with the functions humectant and skin conditioning and no listed restriction; CosIng is an inventory, not an authorisation.
